

# CITATION REPORT

List of articles citing

New concepts in antimalarial use and mode of action in derm

DOI: 10.1111/j.1529-8019.2007.00131.x  
Dermatologic Therapy, 2007, 20, 160-74.

**Source:** <https://exaly.com/paper-pdf/42880211/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
214	[Dermatological symptoms in rheumatology]. <b>2008</b> , 67, 372, 374-8, 380-5		
213	Interventions for cutaneous disease in systemic lupus erythematosus. <b>2008</b> ,		2
212	Ocular toxicity of hydroxychloroquine. <b>2008</b> , 23, 201-9		74
211	Role of dendritic cells in the pathogenesis of systemic lupus erythematosus. <b>2008</b> , 3, 269-279		1
210	Avalia <sup>ç</sup> o do uso da hidroxicloroquina no tratamento da osteoartrite sintom <sup>á</sup> tica de joelhos. <b>2008</b> , 48,		3
209	Inhibition of RNA recruitment and replication of an RNA virus by acridine derivatives with known anti-prion activities. <b>2009</b> , 4, e7376		13
208	Lupus arthritis. <b>2009</b> , 23, 495-506		79
207	Granulomatous disease in common variable immunodeficiency. <b>2009</b> , 133, 198-207		147
206	Autoimmunity in common variable immunodeficiency. <b>2009</b> , 9, 347-52		129
205	Toll-like receptors and dermatology. <b>2009</b> , 48, 558-70		6
204	Does chloroquine therapy of porphyria cutanea tarda influence liver pathology?. <b>2009</b> , 48, 1250-3		12
203	Drug-induced pigmentation of hard palate and skin due to chronic chloroquine therapy: report of two cases. <b>2009</b> , 34, e266-7		12
202	T-cell-mediated injury to keratinocytes: insights from animal models of the lichenoid tissue reaction. <b>2009</b> , 129, 309-14		15
201	Hydroxychloroquine induces autophagic cell death of human dermal fibroblasts: implications for treating fibrotic skin diseases. <b>2009</b> , 129, 2333-5		11
200	Lichenoid Tissue Reaction/Interface Dermatitis: Clinical and Histological Perspectives. <b>2009</b> , 129, 1088-1099		85
199	Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. <b>2009</b> , 61, 177-97		330
198	Targeting Toll-like receptors in autoimmunity. <b>2009</b> , 10, 1139-55		35

197	The place of William Osler in the description of systemic lupus erythematosus. <b>2009</b> , 338, 409-12	9
196	Use of antimalarials in dermatology. <b>2010</b> , 8, 829-44; quiz 845	22
195	Einsatz von Antimalariamitteln in der Dermatologie. <b>2010</b> , 8, 829-846	23
194	Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment. <b>2010</b> , 21, 373-82	21
193	Significant improvement in ulcerative necrobiosis lipoidica with hydroxychloroquine. <b>2010</b> , 49, 467-9	20
192	Treatment of so-called idiopathic follicular mucinosis with hydroxychloroquine. <b>2010</b> , 163, 420-3	17
191	Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. <b>2010</b> , 5, e10685	31
190	Treatment of cutaneous lupus erythematosus. <b>2010</b> , 19, 1125-36	33
189	Cutaneous lupus erythematosus: recent lessons from animal models. <b>2010</b> , 19, 1029-35	15
188	CD4+ CD25+ Foxp3+ regulatory T cells, dendritic cells, and circulating cytokines in uncomplicated malaria: do different parasite species elicit similar host responses?. <b>2010</b> , 78, 4763-72	61
187	Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. <b>2010</b> , 11, 1277-93	32
186	TLR9 blockade inhibits activation of diabetogenic CD8+ T cells and delays autoimmune diabetes. <b>2010</b> , 184, 5645-53	57
185	Reduction of immune activation with chloroquine therapy during chronic HIV infection. <b>2010</b> , 84, 12082-6	108
184	Quinacrine in the Treatment of Cutaneous Lupus Erythematosus: Practical Aspects and a Case Series. <b>2010</b> , 101, 54-58	
183	The lysosome among targets of metformin: new anti-inflammatory uses for an old drug?. <b>2010</b> , 14, 467-78	16
182	Hydroxychloroquine and lichen planopilaris: efficacy and introduction of Lichen Planopilaris Activity Index scoring system. <b>2010</b> , 62, 387-92	121
181	Aspectos pr <sup>á</sup> cticos de la quinacrina como tratamiento del lupus eritematoso cut <sup>á</sup> neo: serie de casos. <b>2010</b> , 101, 54-58	12
180	Modulators of Toll-Like Receptor (TLR) Signaling. <b>2010</b> , 45, 191-207	3

179	The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. <b>2011</b> , 13, 203	40
178	The role of antimalarial agents in the treatment of SLE and lupus nephritis. <b>2011</b> , 7, 718-29	166
177	Autoimmune Diseases of the Skin. <b>2011</b> ,	4
176	Cutaneous lupus erythematosus: update of therapeutic options part I. <b>2011</b> , 65, e179-93	120
175	Antimalarials and SLE. <b>2011</b> , 1061-1081	0
174	Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. <b>2011</b> , 17, 115-20	57
173	Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. <b>2011</b> , 23, 278-81	73
172	Toll-like receptors in rheumatic diseases: are we paying a high price for our defense against bugs?. <b>2011</b> , 585, 3660-6	30
171	Treatment of cutaneous lupus. <b>2011</b> , 13, 300-7	46
170	Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers. <b>2011</b> , 9, 13	89
169	Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon- $\gamma$ production in patients with active disease. <b>2011</b> , 63, 1698-706	90
168	Analytical interference of quinolone antibiotics and quinine derived drugs on urinary protein determined by reagent strips and the pyrogallol red-molybdate protein assay. <b>2011</b> , 44, 1000-4	9
167	Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?. <b>2011</b> , 4, 369-71	8
166	Antimalarial cutaneous side effects: a study in 209 users. <b>2011</b> , 30, 45-9	33
165	Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus". <b>2011</b> , 147, 1267-8	2
164	Therapeutical targeting of nucleic acid-sensing Toll-like receptors prevents experimental cerebral malaria. <b>2011</b> , 108, 3689-94	84
163	Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis. <b>2011</b> , 147, 1261-7	94
162	Chronic non-granulomatous supraglottitis: a rare and difficult disease. <b>2012</b> , 126, 854-7	4

161	Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). <b>2012</b> , 22, 249-255	10
160	Suppression of TLR signaling by targeting TIR domain-containing proteins. <b>2012</b> , 13, 776-88	30
159	Antimalarials for the treatment of rheumatic disease: recent advances and future use. <b>2012</b> , 7, 239-241	
158	Hypertrophic and ulcerated discoid lupus erythematosus. <b>2012</b> , 16, 453-7	3
157	Antimalarials: Reversing the autoimmune threshold. <b>2012</b> , 7, 97-101	
156	Dermatophytoma: description of 7 cases. <b>2012</b> , 66, 1014-6	13
155	Lipodermatosclerosis: improvement noted with hydroxychloroquine and pentoxifylline. <b>2012</b> , 66, 1013-4	11
154	Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects. <b>2012</b> , 42, 968-78	73
153	CIL-102 induces matrix metalloproteinase-2 (MMP-2)/MMP-9 down-regulation via simultaneous suppression of genetic transcription and mRNA stability. <b>2012</b> , 44, 2212-22	10
152	Coding. <b>2012</b> , 1-547	3
151	A Review of Drugs that Induce or Exacerbate Psoriasis. <b>2012</b> , 18a, 2-11	8
150	Nutritional stress and arginine auxotrophy confer high sensitivity to chloroquine toxicity in mesothelioma cells. <b>2012</b> , 46, 498-506	16
149	Synthesis and biological evaluation of acridine derivatives as antimalarial agents. <b>2012</b> , 7, 587-605	25
148	The Manual of Dermatology. <b>2012</b> ,	1
147	Hydroxychloroquine: from malaria to autoimmunity. <b>2012</b> , 42, 145-53	348
146	Cutaneous lupus erythematosus. <i>Dermatologic Therapy</i> , <b>2012</b> , 25, 99-111	2.2 10
145	Malaria's deadly secret: a skin stage. <b>2012</b> , 28, 142-50	25
144	Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study. <b>2012</b> , 39, 531-5	19

143	Chloroquine: modes of action of an undervalued drug. <b>2013</b> , 153, 50-7	92
142	Can rheumatoid arthritis be prevented?. <b>2013</b> , 27, 467-85	35
141	Antipaludicos de síntesis en dermatología. <b>2013</b> , 47, 1-8	
140	Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. <b>2013</b> , 12, 694-702	37
139	Mechanisms of premature atherosclerosis in rheumatoid arthritis and lupus. <b>2013</b> , 64, 249-63	93
138	Pharmacokinetics of immunomodulator treatments after roux-en-y bypass in obese patient. <b>2013</b> , 53, 779-84	2
137	The lysosomal inhibitor, chloroquine, increases cell surface BMPR-II levels and restores BMP9 signalling in endothelial cells harbouring BMPR-II mutations. <b>2013</b> , 22, 3667-79	77
136	Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation. <b>2013</b> , 112, 1159-70	181
135	Antipaludicos de síntesis en dermatología. <b>2013</b> , 8, 1-7	
134	Current and emerging pharmacological treatments for sarcoidosis: a review. <b>2013</b> , 7, 325-38	33
133	Absence of the lysosomal protein Limp-2 attenuates renal injury in crescentic glomerulonephritis. <b>2014</b> , 92, 400-8	3
132	The clinical significance of drug interactions between dermatological and psychoactive medications. <i>Dermatologic Therapy</i> , <b>2014</b> , 27, 1-11	2.2 2
131	Hydroxychloroquine and Chloroquine Retinopathy. <b>2014</b> ,	25
130	Pharmacology of Chloroquine and Hydroxychloroquine. <b>2014</b> , 35-63	65
129	Antipaludicos en dermatología: mecanismo de acción, indicaciones y efectos secundarios. <b>2014</b> , 105, 243-252	27
128	Amsacrine suppresses matrix metalloproteinase-2 (MMP-2)/MMP-9 expression in human leukemia cells. <b>2014</b> , 229, 588-98	22
127	Severe Skin Diseases in Children. <b>2014</b> ,	
126	The immunopathology of cutaneous lupus erythematosus. <b>2014</b> , 40, 455-74, viii	20

125	Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity. <b>2014</b> , 76, 81-9	51
124	Antimalarials in dermatology: mechanism of action, indications, and side effects. <b>2014</b> , 105, 243-52	14
123	Hydroxychloroquine: a multifaceted treatment in lupus. <b>2014</b> , 43, e167-80	101
122	The enigma of the clandestine association between chloroquine and HIV-1 infection. <b>2015</b> , 16, 585-90	26
121	Molecular targets in arthritis and recent trends in nanotherapy. <b>2015</b> , 10, 5407-20	24
120	Acquired facial lipoatrophy: pathogenesis and therapeutic options. <b>2015</b> , 32, 127-33	15
119	Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests. <b>2015</b> , 231, 353-9	22
118	Targeting CD4(+) T cells for the treatment of sarcoidosis: a promising strategy?. <b>2015</b> , 7, 57-66	9
117	Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. <b>2015</b> , 70, 1608-21	258
116	Selective inhibition of extracellular oxidants liberated from human neutrophils--A new mechanism potentially involved in the anti-inflammatory activity of hydroxychloroquine. <b>2015</b> , 28, 175-81	13
115	Current and future treatment options for cutaneous lupus erythematosus. <b>2015</b> , 3, 777-786	
114	Miocardopat <sup>a</sup> dilatada en un paciente con lupus discoide cr <sup>o</sup> nico en tratamiento con mepacrina. <b>2015</b> , 30, 206-208	
113	Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists. <b>2015</b> , 16, 179-95	5
112	Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. <b>2015</b> , 2, 183-195	22
111	Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy. <b>2015</b> , 16, 48-56	45
110	Serum soluble toll-like receptor 2: a novel biomarker for systemic lupus erythematosus disease activity and lupus-related cardiovascular dysfunction. <b>2016</b> , 19, 685-92	18
109	[Hydroxychloroquine for autoimmune diseases]. <b>2016</b> , 144, 232-40	13
108	Frontal Fibrosing Alopecia Coexisting with Lupus Erythematosus: Poor Response to Hydroxychloroquine. <b>2017</b> , 2, 162-165	7

107	[Immunomodulatory therapy of autoimmune diseases : Quo vadis?]. <b>2016</b> , 113, 373-9	0
106	The effect of hydroxychloroquine on lupus erythematosus-like skin lesions in MRL/lpr mice. <b>2016</b> , 26, 744-8	5
105	Autophagy: controlling cell fate in rheumatic diseases. <b>2016</b> , 12, 517-31	77
104	Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 184-90	9.5 81
103	Antimalarial Drugs for the Treatment of Oral Erosive Lichen Planus. <b>2016</b> , 232, 86-90	5
102	Hair analysis of an unusual case of Chloroquine intoxication. <b>2016</b> , 19, 5-10	6
101	CCL2, CXCL8, CXCL9 and CXCL10 serum levels increase with age but are not altered by treatment with hydroxychloroquine in patients with osteoarthritis of the knees. <b>2017</b> , 20, 1958-1964	15
100	Allergic Urticaria. <b>2017</b> , 489-509	
99	Hydroxychloroquine, cold urticaria, and the ice bucket challenge: A case report. <b>2017</b> , 21, 98-99	
98	Updated recommendations on the use of hydroxychloroquine in dermatologic practice. <b>2017</b> , 76, 1176-1182	29
97	Quinacrine Suppresses Tumor Necrosis Factor- $\alpha$ and IFN- $\gamma$ in Dermatomyositis and Cutaneous Lupus Erythematosus. <b>2017</b> , 18, S57-S63	21
96	Antimalarials in cutaneous lupus erythematosus subtypes. <b>2017</b> , 177, 14-15	
95	RELATO DE CASO SOBRE LUPUS ERITEMATOSO SISTÊMICO ASSOCIADO A EVENTOS TROMBOEMBÓLICOS. <b>2017</b> , 57, S191-S192	
94	LUPUS ERITEMATOSO SISTÊMICO EM ASSOCIAÇÃO COM PORFÍRIA CUTÂNEA TARDA: RELATO DE CASO. <b>2017</b> , 57, S192	
93	Desirable and Adverse Effects of Antiinflammatory Agents on the Heart. <b>2017</b> , 617-643	0
92	Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation. <b>2017</b> , 2017, 7807313	45
91	A new insight into effects of a clinically proved combination of methotrexate and hydroxychloroquine. <b>2018</b> , 149, 961-967	
90	Early cutaneous eruptions after oral hydroxychloroquine in a lupus erythematosus patient: A case report and review of the published work. <b>2018</b> , 45, 344-348	12



89	Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. <b>2018</b> , 30, 249-255	33
88	Treatment of lichen planopilaris: methotrexate or cyclosporine a therapy?. <b>2018</b> , 37, 196-199	8
87	Screening of herbal extracts for TLR2- and TLR4-dependent anti-inflammatory effects. <b>2018</b> , 13, e0203907	30
86	Renal Manifestations of Rheumatoid Arthritis. <b>2018</b> , 44, 571-584	16
85	Treating lupus patients with antimalarials: analysis of safety profile in a single-center cohort. <b>2018</b> , 27, 1616-1623	12
84	The role of hydroxychloroquine in catastrophic antiphospholipid syndrome case: Series of two case reports and review of literature. <b>2018</b> , 6, 2050313X18782808	
83	Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. <b>2018</b> , 12, 1685-1695	53
82	Antimalarials - are they effective and safe in rheumatic diseases?. <b>2018</b> , 56, 164-173	51
81	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. <b>2018</b> , 38, 653-671	152
80	Attenuation of antimalarial agent hydroxychloroquine on TNF- $\beta$ induced endothelial inflammation. <b>2018</b> , 63, 261-269	14
79	Antimalarial agents diminish while methotrexate, azathioprine and mycophenolic acid increase BAFF levels in systemic lupus erythematosus. <b>2019</b> , 18, 102372	10
78	In-plane magnetic-field-induced quantum anomalous Hall plateau transition. <b>2019</b> , 100,	13
77	Current Insights Into The Management Of Discoid Lupus Erythematosus. <b>2019</b> , 12, 721-732	10
76	Analyses of Skin and Peripheral Blood Transcriptional Data in Cutaneous Lupus Reveals CCR2-A Novel Potential Therapeutic Target. <b>2019</b> , 10, 640	4
75	Recommendations for photoprotection in pediatric rheumatology patients. <b>2019</b> , 31, 491-497	1
74	Increased Myeloid Dendritic Cells and TNF- $\beta$ Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus. <b>2019</b> , 139, 324-332	20
73	Chloroquine differentially modulates coronary vasodilation in control and diabetic mice. <b>2020</b> , 177, 314-327	6
72	Hydroxychloroquine in dermatology: New perspectives on an old drug. <b>2020</b> , 61, e150-e157	11

71	Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria. <b>2020</b> , 40, 777-783	3
70	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <b>2020</b> , 262, 118541	4
69	Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquine and Hydroxychloroquine. <b>2020</b> , 2020, 4582612	9
68	Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. <b>2020</b> , 108, 1135-1149	17
67	An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. <b>2020</b> , 144, 111639	28
66	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. <b>2020</b> , 9, 561-572	15
65	Repurposing Drugs for COVID-19: Pharmacokinetics and Pharmacogenomics of Chloroquine and Hydroxychloroquine. <b>2020</b> , 13, 531-542	5
64	Psoriasis and Connective Tissue Diseases. <b>2020</b> , 21,	4
63	Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study. <b>2020</b> , 22, 191	8
62	Candidate drug replacements for quinacrine in cutaneous lupus erythematosus. <b>2020</b> , 7,	1
61	Dendritic cells as predictive markers of responsiveness to hydroxychloroquine treatment in primary cicatricial alopecia patients. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14509	2.2
60	Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. <b>2020</b> , 19, 102567	375
59	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. <b>2020</b> , 35, 101735	71
58	A systematic review on use of aminoquinolines for the therapeutic management of COVID-19: Efficacy, safety and clinical trials. <b>2020</b> , 254, 117775	24
57	Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review. <b>2020</b> , 23, 177-181	28
56	Torsades de Pointes in Coronavirus Disease 2019 Infection. <b>2021</b> , 35, 954-955	0
55	Interventions for cutaneous disease in systemic lupus erythematosus. <b>2021</b> , 3, CD007478	4
54	Oral lichen planus: a microbiologist point of view. <b>2021</b> , 24, 275-289	7

53	The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review. <b>2021</b> , 10, 100085	5
52	Analytical Methodologies for Determination of Hydroxychloroquine and Its Metabolites in Pharmaceutical, Biological and Environmental Samples. <b>2021</b> , 17,	0
51	Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. <b>2021</b> , 1	3
50	Therapeutic and Reconstructive Management Options in Scleroderma (Morphea) en Coup de Sabre in Children and Adults. A Systematic Literature Review. <b>2021</b> , 10,	2
49	La piel como reflejo de una enfermedad polimorfa: Sarcoidosis. Reporte de un caso. <b>2021</b> ,	
48	Preclinical Foundations: Relevant Anatomy and Physiology. <b>2014</b> , 1-34	1
47	Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI). <b>2012</b> , 22, 249-55	7
46	Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. <b>2009</b> , 129, 1088-99	25
45	Acute pretreatment with chloroquine attenuates renal I/R injury in rats. <b>2014</b> , 9, e92673	20
44	Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. <b>2020</b> , 58, 2047-2061	4
43	Effect of hydroxychloroquine on oxidative/nitrosative status and angiogenesis in endothelial cells under high glucose condition. <b>2017</b> , 7, 219-226	11
42	Hydroxychloroquine in rheumatic autoimmune disorders and beyond. <b>2020</b> , 12, e12476	29
41	Chloroquine / Hydroxychloroquine: Pharmacological view of an old drug currently used in COVID-19 treatment. 204-215	0
40	Cardiovascular Risk of Synthetic, Non-Biologic Disease-Modifying Anti- Rheumatic Drugs (DMARDs). <b>2020</b> , 18, 455-462	0
39	Systemic Therapy. 1-53	5
38	Chronic Cutaneous Lupus Erythematosus. <b>2011</b> , 193-213	1
37	Connective Tissue Diseases. <b>2011</b> , 155-181	
36	Connective Tissue Disease. <b>2014</b> , 91-122	

- 35 Collagen Vascular Diseases and Cutaneous Drug Reactions. **2015**, 167-180
- 34 Quinacrine pretreatment reduces microwave-induced neuronal damage by stabilizing the cell membrane. **2018**, 13, 449-455 1
- 33 IN SILICO EVALUATION OF POTASSIUM USNATE. **2020**, 8, 524-531
- 32 Targeted Therapies in Autoimmune Skin Diseases. **2021**, 1
- 31 Use of hydroxychloroquine in dermatology: A multicenter retrospective study in Korea. **2021**, 0
- 30 Clinical Probe of Cyp2C8\*2 Mutants in a Malaria Hyperendemic Zone: Evidence from North-Central, Nigeria. **2020**, 63, 119-123 0
- 29 Identification and Development of Therapeutics for COVID-19. **2021**, e0023321 5
- 28 Psychiatric side effects induced by chloroquine and hydroxychloroquine: a systematic review of case reports and population studies. 1
- 27 Effects of Selected Non-biological and Biological Disease-Modifying Anti-rheumatic Drugs, and mRNA Vaccines on Mononuclear Phagocyte System. **2021**,
- 26 Par-4 Secretagogues in Clinical Trials. **2021**, 303-311
- 25 Chemical reagents modulate nucleic acid-activated toll-like receptors.. **2022**, 147, 112622 0
- 24 Iatrogenic Disease and Drug Induced Toxicities Related to Anti-Inflammatory and Immunomodulatory Agents. **2022**, 271-281
- 23 Identification and Development of Therapeutics for COVID-19. **2021**,
- 22 How far are we from predicting multi-drug interactions during treatment for COVID-19 infection?. **2022**,
- 21 Clinical Features, Evaluation, and Management of Lipodermatosclerosis and Chronic Venous Disease literature Review. **2022**, 4, 1
- 20 Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.. **2022**, 9612033221084093 0
- 19 Between a Rock and a Hard Place: Management of Systemic Lupus Erythematosus and Porphyria Cutanea Tarda.. **2022**, 1-11
- 18 Data\_Sheet\_1.PDF. **2019**,

17	Data_Sheet_2.PDF. <b>2019</b> ,		
16	Data_Sheet_3.PDF. <b>2019</b> ,		
15	Data_Sheet_4.PDF. <b>2019</b> ,		
14	Data_Sheet_5.PDF. <b>2019</b> ,		
13	Data_Sheet_6.PDF. <b>2019</b> ,		
12	Data_Sheet_7.PDF. <b>2019</b> ,		
11	Data_Sheet_8.PDF. <b>2019</b> ,		
10	Image_1.TIF. <b>2019</b> ,		
9	Antimalarial agents. <b>2013</b> , 241-251.e3		3
8	Multidimensional immune profiling of cutaneous lupus erythematosus in vivo stratified by patient responses to antimalarials.. <i>Arthritis and Rheumatology</i> , <b>2022</b> ,	9.5	○
7	Redox aspects of cytotoxicity and anti-neuroinflammatory profile of chloroquine and hydroxychloroquine in serum-starved BV-2 microglia. <i>Toxicology and Applied Pharmacology</i> , <b>2022</b> , 116084 <sup>4,6</sup>		
6	QTc Prolongation with the Use of Hydroxychloroquine and Concomitant Arrhythmogenic Medications: A Retrospective Study Using Electronic Health Records Data. <i>Drugs - Real World Outcomes</i> ,	2.2	
5	Hydroxychloroquine pour la sarcoïdose extra-pulmonaire non-séreuse. <i>Revue De Medecine Interne</i> , <b>2022</b> ,	0.1	○
4	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.		○
3	In silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and nonstructural proteins. <b>2022</b> , 313-333		○
2	Systemic Lupus Erythematosus. <b>2023</b> , 167-212		○
1	Hydroxychloroquine Therapy in Sarcoidosis-Associated Uveitis. 1-7		○